help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walsh, B. W.
Right arrow Articles by Anderson, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, B. W.
Right arrow Articles by Anderson, P. W.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 1 214-218
Copyright © 2000 by The Endocrine Society

Original Studies

The Effects of Hormone Replacement Therapy and Raloxifene on C-Reactive Protein and Homocysteine in Healthy Postmenopausal Women: A Randomized, Controlled Trial1

Brian W. Walsh, Sofia Paul, Robert A. Wild, Robert A. Dean, Russell P. Tracy, David A. Cox and Pamela W. Anderson

Brigham and Women’s Hospital (B.W.W.), Boston, Massachusetts 02115; Lilly Research Laboratories (S.P., R.A.D., D.A.C., P.W.A.), Indianapolis, Indiana 46285; Oklahoma University Health Sciences Center (R.A.W.), Oklahoma City, Oklahoma 73190; and University of Vermont (R.P.T.), Burlington, Vermont 05405

Address all correspondence and requests for reprints to: Brian W. Walsh, M.D., Brigham and Women’s Hospital, 75 Francis Street, Boston, Massachusetts 02115. E-mail: bwwalsh{at}bics.bwh.harvard.edu

C-Reactive protein and homocysteine are independent risk factors for the development of cardiovascular disease. This study compared the effects of hormone replacement therapy (HRT) and raloxifene on serum C-reactive protein and homocysteine levels as markers of cardiovascular risk in healthy postmenopausal women. Healthy postmenopausal women (n = 390) were enrolled in a double blind, randomized, placebo-controlled, 6-month trial at eight out-patient sites in the United States. Women were randomly assigned to receive continuous combined HRT (0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate), raloxifene (60 or 120 mg/day), or placebo for 6 months. C-Reactive protein and homocysteine were measured in baseline and 6-month serum samples. HRT increased C-reactive protein levels by 84% (P < 0.001), whereas raloxifene (60 and 120 mg/day) had no significant effect (-6% and -4%, respectively; P > 0.2). Raloxifene (60 and 120 mg/day) significantly lowered serum levels of homocysteine by 8% (P = 0.014) and 6% (P = 0.024), respectively, similar to the 7% (P = 0.014) reduction obtained with HRT.

We conclude that HRT and raloxifene lower serum homocysteine levels to a comparable extent in postmenopausal women. Whereas cardiovascular risk predicted by C-reactive protein in healthy postmenopausal women is not influenced by raloxifene, the relationship between elevated C-reactive protein levels with HRT and cardiovascular disease events requires further study.




This article has been cited by other articles:


Home page
 CirculationHome page
P. Collins, L. Mosca, M. J. Geiger, D. Grady, M. Kornitzer, M. G. Amewou-Atisso, M. B. Effron, S. A. Dowsett, E. Barrett-Connor, and N. K. Wenger
Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors
Circulation, February 24, 2009; 119(7): 922 - 930.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. R. Meendering, B. N. Torgrimson, N. P. Miller, P. F. Kaplan, and C. T. Minson
Estrogen, medroxyprogesterone acetate, endothelial function, and biomarkers of cardiovascular risk in young women
Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1630 - H1637.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
L. A. Viikari, R. K. Huupponen, J. S. A. Viikari, J. Marniemi, C. Eklund, M. Hurme, T. Lehtimaki, M. Kivimaki, and O. T. Raitakari
Relationship between Leptin and C-Reactive Protein in Young Finnish Adults
J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4753 - 4758.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Eng-Wong, J. C. Reynolds, D. Venzon, D. Liewehr, S. Gantz, D. Danforth, E. T. Liu, C. Chow, and J. Zujewski
Effect of Raloxifene on Bone Mineral Density in Premenopausal Women at Increased Risk of Breast Cancer
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3941 - 3946.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J. Y.-P. Ho, M.-J. Chen, W. H.-H. Sheu, Y.-C. Yi, A. C.-W. Tsai, H.-F. Guu, and E. S.-C. Ho
Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women
Hum. Reprod., October 1, 2006; 21(10): 2715 - 2720.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. D. Zoma, R. S. Baker, J. L. Mershon, and K. E. Clark
Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep
Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1216 - H1225.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
M. A. Albert and P. M Ridker
C-Reactive Protein as a Risk Predictor: Do Race/Ethnicity and Gender Make a Difference?
Circulation, August 1, 2006; 114(5): e67 - e74.
[Full Text] [PDF]

Home page
 NEJMHome page
E. Barrett-Connor, L. Mosca, P. Collins, M. J. Geiger, D. Grady, M. Kornitzer, M. A. McNabb, N. K. Wenger, and the Raloxifene Use for The Heart (RUTH) Trial Inve
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
N. Engl. J. Med., July 13, 2006; 355(2): 125 - 137.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S Zanardi, D Serrano, A Argusti, M Barile, M Puntoni, and A Decensi
Clinical trials with retinoids for breast cancer chemoprevention.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 51 - 68.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
Y. Wakugawa, Y. Kiyohara, Y. Tanizaki, M. Kubo, T. Ninomiya, J. Hata, Y. Doi, K. Okubo, Y. Oishi, K. Shikata, et al.
C-Reactive Protein and Risk of First-Ever Ischemic and Hemorrhagic Stroke in a General Japanese Population: The Hisayama Study
Stroke, January 1, 2006; 37(1): 27 - 32.
[Abstract] [Full Text] [PDF]

Home page
 Sci Aging Knowl EnvironHome page
V. L. Ballard and J. M. Edelberg
Harnessing Hormonal Signaling for Cardioprotection
Sci. Aging Knowl. Environ., December 21, 2005; 2005(51): re6 - re6.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
E. Esposito, A. Iacono, G. M. Raso, M. Pacilio, A. Coppola, R. Di Carlo, and R. Meli
Raloxifene, a Selective Estrogen Receptor Modulator, Reduces Carrageenan-Induced Acute Inflammation in Normal and Ovariectomized Rats
Endocrinology, August 1, 2005; 146(8): 3301 - 3308.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Chin, M. Isono, K. Isshiki, S.-i. Araki, T. Sugimoto, B. Guo, H. Sato, M. Haneda, A. Kashiwagi, and D. Koya
Estrogen and Raloxifene, a Selective Estrogen Receptor Modulator, Ameliorate Renal Damage in db/db Mice
Am. J. Pathol., June 1, 2005; 166(6): 1629 - 1636.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Fabian and B. F. Kimler
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Gola, S. Bonadonna, M. Doga, and A. Giustina
Growth Hormone and Cardiovascular Risk Factors
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1864 - 1870.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
S.-Y. Tsang, X. Yao, K. Essin, C.-M. Wong, F. L. Chan, M. Gollasch, and Y. Huang
Raloxifene Relaxes Rat Cerebral Arteries In Vitro and Inhibits L-Type Voltage-Sensitive Ca2+ Channels
Stroke, July 1, 2004; 35(7): 1709 - 1714.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Palomba, F. Orio Jr, T. Russo, A. Falbo, T. Cascella, P. Doldo, C. Nappi, G. Lombardi, P. Mastrantonio, and F. Zullo
Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas
Hum. Reprod., June 1, 2004; 19(6): 1308 - 1314.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
I. R. Reid, R. Eastell, I. Fogelman, J. D. Adachi, A. Rosen, C. Netelenbos, N. B. Watts, E. Seeman, A. V. Ciaccia, and M. W. Draper
A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women
Arch Intern Med, April 26, 2004; 164(8): 871 - 879.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
H. J Teede, F. S Dalais, and B. P McGrath
Dietary soy containing phytoestrogens does not have detectable estrogenic effects on hepatic protein synthesis in postmenopausal women
Am. J. Clinical Nutrition, March 1, 2004; 79(3): 396 - 401.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
R. G. Barr, C. C. Wentowski, F. Grodstein, S. C. Somers, M. J. Stampfer, J. Schwartz, F. E. Speizer, and C. A. Camargo Jr
Prospective Study of Postmenopausal Hormone Use and Newly Diagnosed Asthma and Chronic Obstructive Pulmonary Disease
Arch Intern Med, February 23, 2004; 164(4): 379 - 386.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Palomba, T. Russo, F. Orio Jr, A. Sammartino, F. M. Sbano, C. Nappi, A. Colao, P. Mastrantonio, G. Lombardi, and F. Zullo
Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene
Hum. Reprod., February 1, 2004; 19(2): 415 - 421.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
B. L. Stauffer, G. L. Hoetzer, D. T. Smith, and C. A. DeSouza
Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy
J Appl Physiol, January 1, 2004; 96(1): 143 - 148.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. M Backes, P. A Howard, and P. M Moriarty
Role of C-Reactive Protein in Cardiovascular Disease
Ann. Pharmacother., January 1, 2004; 38(1): 110 - 118.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Barrett-Connor
An Epidemiologist Looks at Hormones and Heart Disease in Women
J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4031 - 4042.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. A. Griffiths, M. A. Sader, M. R. Skilton, J. A. Harmer, and D. S. Celermajer
Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease
J. Am. Coll. Cardiol., August 20, 2003; 42(4): 698 - 704.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. Yilmazer, V. Fenkci, S. Fenkci, O. Aktepe, M. Sonmezer, and G. Kurtay
Association of serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels with hormone replacement therapy in healthy post-menopausal women
Hum. Reprod., July 1, 2003; 18(7): 1531 - 1535.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Silvestri, O. Gebara, C. Vitale, M. Wajngarten, F. Leonardo, J. A.F. Ramires, M. Fini, G. Mercuro, and G. M.C. Rosano
Increased Levels of C-Reactive Protein After Oral Hormone Replacement Therapy May Not Be Related to an Increased Inflammatory Response
Circulation, July 1, 2003; 107(25): 3165 - 3169.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Davison and S. R. Davis
New Markers for Cardiovascular Disease Risk in Women: Impact of Endogenous Estrogen Status and Exogenous Postmenopausal Hormone Therapy
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2470 - 2478.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Colacurci, D. Manzella, F. Fornaro, M. Carbonella, and G. Paolisso
Endothelial Function and Menopause: Effects of Raloxifene Administration
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2135 - 2140.
[Abstract] [Full Text] [PDF]

Home page
 Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
R. A. Whitmer, M. N. Haan, J. W. Miller, and K. Yaffe
Hormone Replacement Therapy and Cognitive Performance: The Role of Homocysteine
J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2003; 58(4): M324 - 330.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. L. Riggs and L. C. Hartmann
Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice
N. Engl. J. Med., February 13, 2003; 348(7): 618 - 629.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
S. A. Jelinsky, H. A. Harris, E. L. Brown, K. Flanagan, X. Zhang, C. Tunkey, K. Lai, M. V. Lane, D. K. Simcoe, and M. J. Evans
Global Transcription Profiling of Estrogen Activity: Estrogen Receptor {alpha} Regulates Gene Expression in the Kidney
Endocrinology, February 1, 2003; 144(2): 701 - 710.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
P. Garnero, C. Jamin, C.-L. Benhamou, C. Pelissier, and C. Roux
Effects of tibolone and combined 17{beta}-estradiol and norethisterone acetate on serum C-reactive protein in healthy post-menopausal women: a randomized trial
Hum. Reprod., October 1, 2002; 17(10): 2748 - 2753.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. Decensi, U. Omodei, C. Robertson, B. Bonanni, A. Guerrieri-Gonzaga, F. Ramazzotto, H. Johansson, S. Mora, M. T. Sandri, M. Cazzaniga, et al.
Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women
Circulation, September 3, 2002; 106(10): 1224 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Cagnacci, A. M. Paoletti, A. Zanni, S. Arangino, G. Ibba, M. Orru, G. B. Melis, and A. Volpe
Raloxifene Does Not Modify Insulin Sensitivity and Glucose Metabolism in Postmenopausal Women
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4117 - 4121.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. D. Pradhan, J. E. Manson, J. E. Rossouw, D. S. Siscovick, C. P. Mouton, N. Rifai, R. B. Wallace, R. D. Jackson, M. B. Pettinger, and P. M Ridker
Inflammatory Biomarkers, Hormone Replacement Therapy, and Incident Coronary Heart Disease: Prospective Analysis From the Women's Health Initiative Observational Study
JAMA, August 28, 2002; 288(8): 980 - 987.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
T. Simoncini, A. R. Genazzani, and J. K. Liao
Nongenomic Mechanisms of Endothelial Nitric Oxide Synthase Activation by the Selective Estrogen Receptor Modulator Raloxifene
Circulation, March 19, 2002; 105(11): 1368 - 1373.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
O. Johnell, W. H. Scheele, Y. Lu, J.-Y. Reginster, A. G. Need, and E. Seeman
Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women with Osteoporosis
J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 985 - 992.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. G. Bostom, P. F. Jacques, G. Liaugaudas, G. Rogers, I. H. Rosenberg, and J. Selhub
Total Homocysteine Lowering Treatment Among Coronary Artery Disease Patients in the Era of Folic Acid-Fortified Cereal Grain Flour
Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 488 - 491.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
E. Barrett-Connor, D. Grady, A. Sashegyi, P. W. Anderson, D. A. Cox, K. Hoszowski, P. Rautaharju, K. D. Harper, and for the MORE Investigators
Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial
JAMA, February 20, 2002; 287(7): 847 - 857.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
R. Marcus, M. Wong, H. Heath III, and J. L. Stock
Antiresorptive Treatment of Postmenopausal Osteoporosis: Comparison of Study Designs and Outcomes in Large Clinical Trials with Fracture as an Endpoint
Endocr. Rev., February 1, 2002; 23(1): 16 - 37.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Andersson, G. Johannsson, G. Holm, B.-A. Bengtsson, A. Sashegyi, I. Pavo, T. Mason, and P. W. Anderson
Raloxifene Does Not Affect Insulin Sensitivity or Glycemic Control in Postmenopausal Women with Type 2 Diabetes Mellitus: A Randomized Clinical Trial
J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 122 - 128.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. C. Jordan, S. Gapstur, and M. Morrow
Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease
J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. H.-J. Hsu, W.-C. Cheng, M.-W. Jang, and K.-S. Tsai
Effects of Long-Term Use of Raloxifene, a Selective Estrogen Receptor Modulator, on Thyroid Function Test Profiles
Clin. Chem., October 1, 2001; 47(10): 1865 - 1867.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. M. Herrington, K. B. Brosnihan, B. E. Pusser, E. W. Seely, P. M. Ridker, N. Rifai, and D. B. MacLean
Differential Effects of E and Droloxifene on C-Reactive Protein and Other Markers of Inflammation in Healthy Postmenopausal Women
J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4216 - 4222.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. Saitta, D. Altavilla, D. Cucinotta, N. Morabito, N. Frisina, F. Corrado, R. D'Anna, A. Lasco, G. Squadrito, A. Gaudio, et al.
Randomized, Double-Blind, Placebo-Controlled Study on Effects of Raloxifene and Hormone Replacement Therapy on Plasma NO Concentrations, Endothelin-1 Levels, and Endothelium-Dependent Vasodilation in Postmenopausal Women
Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1512 - 1519.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. D. P. Luyer, S. Khosla, W. G. Owen, and V. M. Miller
Prospective Randomized Study of Effects of Unopposed Estrogen Replacement Therapy on Markers of Coagulation and Inflammation in Postmenopausal Women
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3629 - 3634.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
S. Yamada, T. Gotoh, Y. Nakashima, K. Kayaba, S. Ishikawa, N. Nago, Y. Nakamura, Y. Itoh, and E. Kajii
Distribution of Serum C-Reactive Protein and Its Association with Atherosclerotic Risk Factors in a Japanese Population : Jichi Medical School Cohort Study
Am. J. Epidemiol., June 15, 2001; 153(12): 1183 - 1190.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
R. P. Tracy
Is Visceral Adiposity the "Enemy Within"?
Arterioscler Thromb Vasc Biol, June 1, 2001; 21(6): 881 - 883.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
N. N. Chan, T. M.M. Tan, and S. J. Hurel
Hyperhomocysteinemia and Macroangiopathy in Type 2 Diabetes
Diabetes Care, June 1, 2001; 24(6): 1123 - 1124.
[Full Text]

Home page
 Diabetes CareHome page
M. Buysschaert and M.P. Hermans
Response to Chan et al.: Hyperhomocysteinemia and Macroangiopathy in Type 2 Diabetes
Diabetes Care, June 1, 2001; 24(6): 1124 - 1125.
[Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Sesmilo, B. M. K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, and A. Klibanski
Effects of Growth Hormone (GH) Administration on Homocyst(e)ine Levels in Men with GH Deficiency: A Randomized Controlled Trial
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1518 - 1524.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Cushman, J. P. Costantino, R. P. Tracy, K. Song, L. Buckley, J. D. Roberts, and D. N. Krag
Tamoxifen and Cardiac Risk Factors in Healthy Women : Suggestion of an Anti-inflammatory Effect
Arterioscler Thromb Vasc Biol, February 1, 2001; 21(2): 255 - 261.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2000 by The Endocrine Society